Sam Brusco03.30.22
InnovHeart, maker of the Saturn transcatheter mitral valve replacement (TMVR) system, has appointed experienced healthcare and medical device executive David James Wilson as its new CEO and executive member of the board of directors.
Wilson spent two decades with various Johnson & Johnson companies, including serving as the worldwide president of Cordis where he led its integration in to Cardinal Health. He was also president of J&J’s Mentor, VP of J&J’s Ethicon R&D, and VP of J&J’s Ethicon Biosurgicals.
Before J&J, he served as Cordis Endovascular’s VP of R&D and regional director of sales. He was most recently president of Global Plasma at Haemonetics. Wilson holds ten medical device patents and has been a board member for several U.S. healthcare and educational institutions.
"I am excited to join the talented team at InnovHeart at this pivotal time of focus and commitment to significantly advancing TMVR procedures enabled by our transformational Saturn platform," Wilson told the press. "The innovative Saturn technology has the potential to be life changing for patients with regurgitant mitral valves and I'm eager to further the clinical validation of the trans-septal Saturn system."
Dr. Keith Dawkins, Chairman of the company, added, "This is an important time for InnovHeart as we transition from a trans-apical to a trans-septal delivery of the Saturn valve. We have been encouraged by the outstanding medium term results of the trans-apical system, and we fully anticipate that the best-in-class hemodynamics will be reflected in the first-in-human implantation of the same Saturn valve trans-septally. David's range of leadership skills will further enhance the commitment, drive and engineering prowess of the strong InnovHeart Team."
"We welcome with great pleasure David's decision to take the lead of InnovHeart. His broad business and operational leadership attributes will effectively drive the Company through the forthcoming clinical validation of the Saturn trans-septal TMVR system. With David's guidance, we will succeed in raising the Saturn technology to become the pioneering technology in the TMVR space," said Giovanni Righini, founder and chief technology officer of InnovHeart.
Wilson spent two decades with various Johnson & Johnson companies, including serving as the worldwide president of Cordis where he led its integration in to Cardinal Health. He was also president of J&J’s Mentor, VP of J&J’s Ethicon R&D, and VP of J&J’s Ethicon Biosurgicals.
Before J&J, he served as Cordis Endovascular’s VP of R&D and regional director of sales. He was most recently president of Global Plasma at Haemonetics. Wilson holds ten medical device patents and has been a board member for several U.S. healthcare and educational institutions.
"I am excited to join the talented team at InnovHeart at this pivotal time of focus and commitment to significantly advancing TMVR procedures enabled by our transformational Saturn platform," Wilson told the press. "The innovative Saturn technology has the potential to be life changing for patients with regurgitant mitral valves and I'm eager to further the clinical validation of the trans-septal Saturn system."
Dr. Keith Dawkins, Chairman of the company, added, "This is an important time for InnovHeart as we transition from a trans-apical to a trans-septal delivery of the Saturn valve. We have been encouraged by the outstanding medium term results of the trans-apical system, and we fully anticipate that the best-in-class hemodynamics will be reflected in the first-in-human implantation of the same Saturn valve trans-septally. David's range of leadership skills will further enhance the commitment, drive and engineering prowess of the strong InnovHeart Team."
"We welcome with great pleasure David's decision to take the lead of InnovHeart. His broad business and operational leadership attributes will effectively drive the Company through the forthcoming clinical validation of the Saturn trans-septal TMVR system. With David's guidance, we will succeed in raising the Saturn technology to become the pioneering technology in the TMVR space," said Giovanni Righini, founder and chief technology officer of InnovHeart.